ARE is set to report Q4 results on Jan. 26, with the consensus pointing to lower revenues and adjusted FFO as occupancy pressures weigh on performance.
Most REIT dividends are safe going into 2026. But there are exceptions that I expect to cut their dividend. I highlight 3 examples of potential dividend disasters.
Retail investors repeatedly make avoidable mistakes that erode returns, especially in dividend investing. Before asking how to invest $100,000, let's look at how not to. Here are 5 blunders that you should avoid.
Evaluate the expected performance of Alexandria Real Estate Equities (ARE) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Alexandria Real Estate (ARE), a leading life science REIT, now faces a severe industry supply-demand imbalance that is driving rising vacancies, falling occupancy, and negative cash rental spreads. Known FY26 lease expirations will create a roughly 4% annual rental revenue headwind that is likely to persist for most of the year. To salvage occupancy, ARE is more than doubling property-enhancing capex intensity to about 29.5% of NOI, significantly raising the cost to secure and retain tenants.
Not all REITs are worth holding going into 2026. Large unrealized losses make it tempting to book tax losses. I highlight some popular REITs that I would sell if I owned them.
Alexandria Real Estate is a distressed, high-quality life science REIT trading at a steep discount after a dividend cut and operational headwinds. ARE faces declining occupancy, pressured FFO, and elevated leverage but maintains a manageable debt maturity profile and investment-grade tenant base. Management prioritizes balance sheet strength and development pipeline over share repurchases, despite the stock's deep undervaluation on FFO and yield metrics.
Alexandria Real Estate Equities, Inc. (ARE) Analyst/Investor Day Transcript
Alexandria Real Estate Equities cut its dividend by 45%, reflecting persistent macro headwinds and sector-specific challenges. I maintain a Hold rating on ARE, citing anticipated continued pain through 2026–2027 due to declining occupancy and oversupply in life sciences. Recent financials show AFFO down 6.3% and NOI down 6.1% year-over-year, with management lowering full-year guidance and projecting further declines.
ARE's steep dividend cut underscores deep strain from collapsing life science demand and forces it into asset sales and tighter cost controls.
Alexandria Real Estate Equities lowered guidance and cut the dividend. FFO guidance from management came in below almost all analyst estimates. ARE's long-term investment case is weaker than ever, though a short-term technical bounce may be possible after recent sharp declines.
Alexandria Real Estate Equities (ARE) reported earnings 30 days ago. What's next for the stock?